Omnicell, Inc. (NASDAQ:OMCL) Position Reduced by State of Alaska Department of Revenue

State of Alaska Department of Revenue trimmed its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 2.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,664 shares of the company’s stock after selling 659 shares during the quarter. State of Alaska Department of Revenue owned approximately 0.05% of Omnicell worth $897,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in OMCL. Smartleaf Asset Management LLC boosted its stake in Omnicell by 51.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock valued at $35,000 after acquiring an additional 273 shares during the last quarter. Johnson Financial Group Inc. bought a new position in Omnicell during the 4th quarter valued at $37,000. Headlands Technologies LLC bought a new position in Omnicell during the 4th quarter valued at $53,000. First Horizon Advisors Inc. boosted its stake in Omnicell by 36.3% during the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock valued at $59,000 after acquiring an additional 355 shares during the last quarter. Finally, Huntington National Bank boosted its stake in Omnicell by 236.4% during the 4th quarter. Huntington National Bank now owns 1,359 shares of the company’s stock valued at $61,000 after acquiring an additional 955 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors.

Omnicell Stock Up 0.3%

OMCL stock opened at $28.84 on Friday. The company has a quick ratio of 1.23, a current ratio of 1.38 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a fifty-two week low of $22.66 and a fifty-two week high of $55.75. The firm’s 50-day simple moving average is $29.27 and its 200 day simple moving average is $35.94. The stock has a market cap of $1.35 billion, a PE ratio of 62.70 and a beta of 0.78.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.16 by $0.10. Omnicell had a net margin of 1.87% and a return on equity of 4.60%. The business had revenue of $269.67 million for the quarter, compared to analysts’ expectations of $260.18 million. During the same quarter last year, the company earned $0.03 EPS. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. As a group, sell-side analysts predict that Omnicell, Inc. will post 1.09 EPS for the current year.

Wall Street Analyst Weigh In

OMCL has been the topic of a number of research analyst reports. Piper Sandler reiterated an “overweight” rating on shares of Omnicell in a research note on Friday, May 23rd. Benchmark reduced their price target on shares of Omnicell from $62.00 to $40.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. Bank of America raised their price target on shares of Omnicell from $30.00 to $34.00 and gave the stock a “neutral” rating in a research report on Friday, May 23rd. Wells Fargo & Company restated an “overweight” rating and issued a $37.00 price target (up from $35.00) on shares of Omnicell in a research report on Friday, May 23rd. Finally, JPMorgan Chase & Co. reduced their price target on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday, March 20th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $44.83.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.